ChemBriefNovo Nordisk Q3 profit beats forecast; raises 2026 guidance
Novo Nordisk reported third-quarter adjusted operating profit above expectations and raised its full-year profit and sales outlook.
reuters · 2026-11-03 22:36
← TagsEvent
Novo Nordisk AI deal
Novo Nordisk exceeded third-quarter profit expectations and upgraded its full-year and 2026 financial outlook. This indicates strong operational performance and confidence in future demand. The pharma sector benefits from robust demand for metabolic treatments, signaling sustained growth in obesity and diabetes therapies. Market sentiment remains positive for companies with successful pipeline assets. Higher guidance strengthens Novo Nordisk's market valuation and liquidity for potential R&D expansion. It reinforces their dominant position against competitors in the weight-loss drug segment.
15 articles
Novo Nordisk Open to New York Listing Upgrade, CEO Doustdar Tells FT
Novo Nordisk is exploring a direct listing on the New York Stock Exchange to replace current American depositary receipts and boost its US profile. CEO Mike Doustdar confirmed the potential move durin
reuters · 2026-09-22 21:13
Novo Nordisk Faces Calls to Map Out Strategy Beyond Weight-Loss Drugs
Novo Nordisk faces investor pressure to diversify beyond its blockbuster weight-loss drugs amid rising competition from Eli Lilly and impending semaglutide patent expiries. Analysts suggest acquisitio
reuters · 2026-09-20 22:02
Novo partners with Anthropic to speed up drug development with Claude
Novo Nordisk has partnered with Anthropic to integrate Claude AI models into its R&D workflows for accelerated drug discovery. The collaboration aims to shorten research timelines and improve scientif
reuters · 2026-09-16 06:15
Novo Nordisk launches Wegovy weight-loss pill in Germany
Novo Nordisk launched its oral Wegovy weight-loss pill in Germany following EU approval, intensifying competition with Eli Lilly in the expanding GLP-1 market. This semaglutide-based treatment targets
reuters · 2026-09-01 01:55
Novo Nordisk Regains Momentum in Obesity Drug Race Against Eli Lilly
Novo Nordisk shares climbed 35% as its oral Wegovy competes strongly against Eli Lilly's Zepbound in the projected $100 billion obesity market. Investors await Q2 results to assess the durability of t
reuters · 2026-08-02 22:02
Novo Nordisk Launches Weekly Insulin Awiqli in India as Diabetes Burden Rises
Novo Nordisk launched its once-weekly basal insulin Awiqli in India to treat type 1 and 2 diabetes. The product reduces injection frequency to 52 times yearly, competing in a market projected to reach
reuters · 2026-07-08 23:23
Hacking Group Claims Major Breach of Novo Nordisk, Demands $25 Million
Cyber extortion group FulcrumSec claims to have stolen over a terabyte of data from Novo Nordisk, including drug trial information and production facility details, after demanding a $25 million ransom
reuters · 2026-06-16 10:47
Novo Nordisk to seek regulatory approval for Wegovy pill in China soon, says CEO
Novo Nordisk plans to seek Chinese regulatory approval for its oral Wegovy pill very soon, CEO Mike Doustdar said. The company aims to compete with Eli Lilly in China's rapidly expanding GLP-1 market,
reuters · 2026-06-15 23:00
Novo Nordisk Flags Patient Data Breach from Some Clinical Trials in Cyberattack
Novo Nordisk confirmed a cyberattack where unauthorized copies of patient data from certain clinical trials were taken. While core operations remain unaffected, the company has launched an investigati
reuters · 2026-06-11 08:45
Global Firms Bring More Work In-House at India Hubs on AI Boost
Driven by AI productivity, global companies are shifting core functions to in-house India hubs, with Novo Nordisk expanding its role in drug launch preparations.
reuters · 2026-05-26 03:43
Novo Nordisk's first-quarter profit beats forecasts
Novo Nordisk reported a first-quarter operating profit of $5.16 billion, surpassing forecasts amidst intensifying competition with Eli Lilly in the obesity drug market. The company aims to recover fro
reuters · 2026-05-05 22:36
Novo Nordisk's Oral GLP-1 Drug Meets Primary Goal in Late-Stage Diabetes Study
Novo Nordisk announced its oral GLP-1 drug successfully met the primary endpoint in a late-stage study involving children and adolescents aged 10 to 17 with type 2 diabetes.
reuters · 2026-04-23 02:23
Wegovy-maker Novo Nordisk partners with OpenAI to speed drug development
Novo Nordisk partners with OpenAI to deploy AI across drug discovery, manufacturing, and supply chains. The move aims to boost efficiency and competitiveness in the lucrative weight-loss drug market,
reuters · 2026-04-13 23:04
Novo Nordisk Taps Start-Up for New Oral Weight-Loss Drugs
Novo Nordisk has partnered with Vivtex Corporation to license oral drug-delivery technologies for weight loss and diabetes, agreeing to pay up to $2.1 billion in milestone payments.
cen · 2026-02-25 00:00